Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA

Key Points

• Cyndeo Wealth Partners LLC invested $101,000 in Intellia Therapeutics, acquiring 10,715 shares, highlighting growing institutional interest in the company.
• Insiders recently sold over 9,000 shares of Intellia Therapeutics, indicating a decrease in ownership, with EVP Edward J. Dulac III selling 7,462 shares for approximately $104,617.
• Analysts have varied opinions on NTLA stock, with price targets ranging from $14.00 to $60.00, and a consensus rating of Moderate Buy amid a strong revenue growth year-over-year.

Cyndeo Wealth Partners LLC bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,715 shares of the company's stock, valued at approximately $101,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its holdings in Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after purchasing an additional 1,655 shares during the last quarter. Harbour Investments Inc. increased its holdings in Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after purchasing an additional 2,264 shares during the last quarter. Quantbot Technologies LP increased its holdings in Intellia Therapeutics by 846.4% in the 1st quarter. Quantbot Technologies LP now owns 6,663 shares of the company's stock valued at $47,000 after purchasing an additional 5,959 shares during the last quarter. GAMMA Investing LLC increased its holdings in Intellia Therapeutics by 1,961.2% in the 1st quarter. GAMMA Investing LLC now owns 7,544 shares of the company's stock valued at $540,000 after purchasing an additional 7,178 shares during the last quarter. Finally, 49 Wealth Management LLC acquired a new stake in Intellia Therapeutics in the 1st quarter valued at approximately $74,000. Institutional investors and hedge funds own 88.77% of the company's stock.

Insider Transactions at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer directly owned 55,266 shares of the company's stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 9,364 shares of company stock valued at $137,674. Insiders own 3.10% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on NTLA shares. Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Wells Fargo & Company reiterated an "overweight" rating and issued a $45.00 target price (down previously from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Wednesday. HC Wainwright boosted their price target on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Finally, Chardan Capital dropped their price target on shares of Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Thirteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $27.95.

Intellia Therapeutics Trading Down 3.7%

Intellia Therapeutics stock opened at $24.52 on Friday. The stock has a market cap of $2.63 billion, a P/E ratio of -5.23 and a beta of 2.37. The company has a fifty day simple moving average of $13.97 and a 200-day simple moving average of $10.81. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $26.99.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to analysts' expectations of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The company's revenue for the quarter was up 104.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.52) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.